Preclinical models of Parkinson's disease (PD) have been developed using intracerebroventricular (i.c.v.) injection of 6-hydroxydopamine (6-OHDA) to induce neurodegeneration and motor dysfunction.
The California Department of Insurance has been under pressure to stabilize the market, introducing new rules that allow ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback